Phreesia (NYSE:PHR) Receives Market Perform Rating from Citizens Jmp

Citizens Jmp reaffirmed their market perform rating on shares of Phreesia (NYSE:PHR) in a research note published on Wednesday, Marketbeat reports.

Other research analysts also recently issued reports about the company. Barclays dropped their target price on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 16th. DA Davidson lowered their price target on Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Wells Fargo & Company lowered their price target on Phreesia from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, March 26th. Stephens dropped their price target on Phreesia from $32.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Citigroup reaffirmed a “neutral” rating and issued a $10.00 price objective (down from $25.00) on shares of Phreesia in a research report on Tuesday. Twelve analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Phreesia Price Performance

Shares of PHR opened at $8.40 on Wednesday. The company has a market cap of $506.35 million, a price-to-earnings ratio of 279.97 and a beta of 0.67. Phreesia has a twelve month low of $7.77 and a twelve month high of $32.76. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $12.21 and a two-hundred day moving average of $17.51.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The business had revenue of $127.07 million for the quarter, compared to analyst estimates of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.11) earnings per share. As a group, analysts predict that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insider Transactions at Phreesia

In other Phreesia news, insider David Linetsky sold 6,106 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $103,863.06. Following the sale, the insider owned 231,723 shares in the company, valued at approximately $3,941,608.23. The trade was a 2.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 6,585 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $112,010.85. Following the completion of the transaction, the general counsel directly owned 174,762 shares in the company, valued at $2,972,701.62. This represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 70,358 shares of company stock worth $1,123,569. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently modified their holdings of the company. Granahan Investment Management LLC increased its holdings in Phreesia by 73.8% in the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after buying an additional 1,018,987 shares during the period. Prosight Management LP acquired a new stake in Phreesia during the 4th quarter valued at approximately $16,533,000. Millennium Management LLC lifted its stake in Phreesia by 730.7% during the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock valued at $25,028,000 after acquiring an additional 936,033 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Phreesia in the 4th quarter valued at $15,213,000. Finally, Greenhouse Funds LLLP increased its stake in shares of Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after acquiring an additional 557,265 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Q4 operating results showed revenue growth and much stronger free cash flow, giving a fundamental floor under the shares; transcripts and presentations highlight record revenue growth and improving FCF. Earnings Presentation
• Positive Sentiment: Stephens lowered its price target but kept an “overweight” stance (new PT $20), signaling some analysts still see sizable upside from current levels despite weaker guidance. Stephens Coverage
• Neutral Sentiment: Multiple firms reiterated neutral/hold or market‑perform ratings (JPMorgan, Robert W. Baird, Citigroup, Truist, Citizens Jmp) while trimming price targets — this keeps the stock in analysts’ coverage but signals cautious sentiment. Analyst Radar
• Negative Sentiment: Management cut FY2027 revenue guidance to $510M–$520M (from $545M–$559M), citing reduced visibility into pharma client spending and weaker H2 commitments — the guidance cut is the primary driver of recent heavy selling. Guidance Coverage
• Negative Sentiment: Shares plunged after the outlook cut and several firms lowered price targets (examples: Needham, BMO, Canaccord lowered targets; multiple downgrades and PT trims followed the guidance update), increasing near-term downside risk. Downgrades Coverage
• Negative Sentiment: Levi & Korsinsky has opened an investigation into potential securities-law violations related to Phreesia, introducing legal/uncertainty risk that can amplify volatility and weighing on sentiment. Investigation Notice
• Negative Sentiment: Some sell-side commentary withdrew buy recommendations or explicitly flagged disappointment with the growth outlook, which can pressure flows and limit short‑term buyers. Analyst Reaction

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.